Drug intelligence / Profile preview

BMS-986488 + nivolumab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**BMS-986488 + nivolumab** is an experimental combination therapy being studied for the treatment of advanced malignant tumors, particularly clear cell renal cell carcinoma. BMS-986488 is a novel immunotherapy agent with an undisclosed mechanism of action currently in phase 1 trials; it is investigated in combination with **nivolumab**, a well-established anti–programmed death-1 (PD-1) monoclonal antibody that blocks the PD-1 receptor on T-cells, thereby enhancing anti-tumor immune response. The combination is designed to potentiate immune-mediated anti-cancer activity and is being tested for safety, tolerability, and preliminary efficacy in solid tumors, mainly advanced or metastatic clear cell renal cell carcinoma[1][2][5][8].

Other names: BMS-986488 + nivolumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on BMS-986488 + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986488 + nivolumab.

Explore the full profile